Juan Carlos Ruiz Cobo

MD. Hospital Vall d'Hebron. Hepatology. Gastroenterology. Viral hepatitis - towards elimination. Inmune liver diseases. Santander - Madrid - Barcelona

[Jose M Remes Troche @chemaremes]

🧵 HILO: Neuromoduladores en Gastroenterología

1️⃣ Los Trastornos de la Interacción Cerebro-Intestino (TICI) afectan el procesamiento central y periférico de estímulos en el eje cerebro-intestino. Incluyen dispepsia funcional, gastroparesia y SII. ¡Su tratamiento clave son los neuromoduladores! 🧠🦠 Todo lo que desees saber aqui https://t.co/93JI4C88xY @gastromx @motilidad @CidemoArgentina @ASENEM_ @aeg @drprapul @DraBarba @DeMadaria @coss_enriquemd @GastroMty @CMIMorg @pepebandera1 @velardemd @ConchaAlejandro @OPGEgastro @OxytocinLau

[Asociación Española para el Estudio del Hígado @AEEHLiver]

#AEEH2025.
➡️'Hepatolotoxicidad por inhibidores de CDK4/6 en cáncer de mama metastático (CMM)', con @mar_riveiro (ganadora de una de las #Becas Gilead-AEEH).
✔️Un estudio multicéntrico que todavía está en marcha.
🗣️"El manejo del #DILI por CDKi es heterogéneo, y su
estandarización es una necesidad de futuro dada la reciente aprobación de #ribociclib y #abemaciclib en el contexto adyuvante, explica Mar. @LHuvh @CIBERehd #50CongresoAEEH

[Carl Kay, MD @CarlKayMD]

🆕 @AmerGastroAssn Guidelines for Prevention & Treatment of Hepatitis B Virus Reactivation in At-Risk Individuals

▪️HBsAg (+)
▪️HBsAg (-), HBcAB (+)

🚨B-cell depleting agents
🚨Anthracycline
🚨Anti-TNF
🚨Anti-IL6
🚨Cytokine inh
🚨CAR-T
🚨TACE
🚨JAKi

🔗 https://t.co/WNTXJ09Cll

[Luis Téllez @luistevilla]

🚨🚨Happy to share our last paper!!!🚨🚨

Non-invasive assessment of severe liver fibrosis in patients with Fontan-associated liver disease: The VALDIG-EASL FONLIVER cohort - Journal of Hepatology https://t.co/ujR1Mz1jjL

[William Chey @umfoodoc]

ACG Clinical Practice guideline on H. pylori was published in ⁦@AmJGastro⁩ today. Visual abstract gives a great summary. Thanks to my co authors! ⁦@ShailjaShahMD⁩

[Spanish DILI Registry @SDILI_Registry]

🗞️New article ▶️effectiveness of sofosbuvir/velpatasvir/voxilaprevir in hepatitis C patients @APandT @DigestivoHuvv @_ibima @JCRCobo @DrJLCalleja @Mariabutif 👇
https://t.co/ZOvhyuMR4M

[Miguel R. Gandía @RodriguezGandia]

Efficacy and safety of carvedilol in cirrhosis patients with uncomplicated ascites without high-risk esophageal varices, RCT

Carvedilol less
Complicated ascites
Refractory ascitis
Mortality
90% men

#EASLCongress #WeShareEASL

[Victor Vargas @vvargasb]

Elena Vargas-Accarino presenting and discussing her poster on hepatitis C screening in primary care setting - EASL Congress 2024

[Journal of Hepatology @JHepatology]

🆕Article in press❕

Bulevirtide monotherapy in patients with chronic HDV: Efficacy and safety results through week 96 from a phase 3 randomized trial

#OpenAccess here👉https://t.co/gCdNbI0Kcm

#LiverTwitter

[Aparato Digestivo @DigesGomezUlla]

PoCUS en lesión renal asociado a cirrosis en @AEcodigest por el Dr @Tubulocentric
Interesante charla👈
💡La ecografía aporta información en el paciente cirrotico, más allá del cribado, ascitis o Trombosis
♦️ Importante: evaluar la congestión del paciente cirrótico
#AEED2024

[JHEP Reports @JHEP_Reports]

🟪NEW Article in press❕

Sarcopenia evaluated by EASL/AASLD computed tomography-based criteria predicts mortality in patients with #cirrhosis: a systematic review and meta-analysis

🔓#OpenAccess at 👉https://t.co/dNN6tH4mRs

#LiverTwitter
@EASLedu
@AASLDtweets

[Juan Carlos Ruiz Cobo @JCRCobo]

Happy to share results from Hepa-C registry! @AEEHLiver

SOF/VEL/VOX is an effective rescue therapy💊 for patients with #HCV 🦠infection who failed to first line therapies without differences between SOF/VEL or GLE/PIB prior treatment >>> 88.6% SVR

https://t.co/uIL6Sami7v

[Eduardo R Argaiz @ArgaizR]

Fantastic collaboration with 🇪🇸 #POCUS experts! @Derasnef @EmiliSanAlv @JaimeMazonRuiz @Tubulocentric

Acute Kidney Injury and Point-of-Care Ultrasound in Liver Cirrhosis: Redefining Hepatorenal Syndrome

https://t.co/uVmpx4Jgj6

[LiverUnit_VallHebron @LHuvh]

Adriana Palom from our Liver Unit @LHuvh presenting the influence of RNA-HDV on clinical events of #HDV patients at #AEEH2024
@VHIR_ @CIBERehd @AEEHLiver

[roypounder.apt @APandT]

Read Open Access "An algorithm based on immunotherapy discontinuation and liver biopsy spares corticosteroids in two thirds of cases of severe checkpoint inhibitor-induced liver injury" by Riveiro-Barciela at https://t.co/UOekiAXUWi
#livertwitter #immunotherapy

[Luis Téllez @luistevilla]

Management of liver and gastrointestinal toxicity induced by immune checkpoint inhibitors: Position statement of the AEEH–AEG–SEPD–SEOM–GETECCU - ScienceDirect https://t.co/RHHeGhfTgJ

[Adriana Palom @adrianapalom24]

Inaugurem la setmana de les malalties hepàtiques a Catalunya! @LHuvh @vallhebron @AEEHLiver

[UACC Vall d’Hebron @UACC_VHebron]

No todo van a ser sesiones en bata😷, gran noche del talento joven digestivo del @vallhebron ✨🩺🚑 @LHuvh

@cherreradeguise @Albajmasip @alcala_glez_LG @sergio_g_mm @SerraXevi @elecesmar

[Journal of Hepatology @JHepatology]

🆕Article in press❕

The adjusted prevalence of hepatitis delta virus (#HDV) in 25 countries and territories

🔓#OpenAccess at👉https://t.co/oaqYNe4DVn

@PolarisObserv
#LiverTwitter

[raulvelamazan @raulvelamazan]

Venga Barceloneses, este año es el primero que corremos en la ciudad!

Vamos a quedarnos por detrás de Madrid y Alicante??🏃🏃🏃

Apúntate ya! ⤵️